It was further found that patients with low RRBP1 expression in UTUC samples were more sensitive to cisplatin, gemcitabine, epirubicin, and other drugs, providing a reference for treatment strategies. This evidence concerns the gene RRBP1 and renal pelvis/ureter urothelial carcinoma.